In Trading, Results Matter.
Our Top 10 exits in last 5 trading days.

Athersys, Inc.. Trade Record

NASDAQ:ATHX Athersys, Inc. stock gains 5.16% Exit Sep 19, 2019 a Trade Record by priceseries

Trade Chart
Trade Chart ATHX Sep 6, 2019, priceSeries
About Athersys, Inc.

Athersys, Inc., a biotechnology company, focuses on the research and development activities in the field of regenerative medicine. Its clinical development programs are focused on treating neurological conditions, cardiovascular diseases, inflammatory and immune disorders, and pulmonary and other conditions. The company's lead platform product includes MultiStem cell therapy, an allogeneic stem cell product, which has completed Phase 2 study for treating patients suffering from moderate and severe ischemic stroke; that is in Phase 2 clinical study for treating patients with acute myocardial infarction; and, which is in Phase 1/2 clinical study for treating patients with acute respiratory distress syndrome, as well as completed Phase 1 clinical study for patients suffering from leukemia or various other blood-borne cancers. It also develops MultiStem cell therapy to promote tissue repair and healing for animal patients; and 5HT2c agonists for the treatment of obesity and other conditions. The company has license and collaboration agreements with Healios K.K. and Chugai Pharmaceuticals Co., Ltd. to develop and commercialize MultiStem cell therapy for ischemic stroke; RTI Surgical, Inc. to develop and commercialize biologic implants for orthopedic applications in the bone graft substitutes market; University of Minnesota to develop MultiStem cell therapy platform; and Bristol-Myers Squibb Company to provide cell lines expressing well validated drug targets for compound screening and development. Athersys, Inc. was founded in 1995 and is headquartered in Cleveland, Ohio.

Trade Information
Trade Type
LONG
ReliabilityScore™
92.16
Entry Date
Sep 6, 2019
Entry Price
1.38
Sell Date
Sep 19, 2019
Sell Price
1.45
Net Gain
5.16%
Hold Time
9 Trading Days